Apellis Pharmaceuticals Inc (APLS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Apellis Pharmaceuticals Inc stock (APLS) is currently trading at $17.72. Apellis Pharmaceuticals Inc PE ratio is 95.61. Apellis Pharmaceuticals Inc PS ratio (Price-to-Sales) is 2.19. Analyst consensus price target for APLS is $33.40. WallStSmart rates APLS as Sell.
- APLS PE ratio analysis and historical PE chart
- APLS PS ratio (Price-to-Sales) history and trend
- APLS intrinsic value — DCF, Graham Number, EPV models
- APLS stock price prediction 2025 2026 2027 2028 2029 2030
- APLS fair value vs current price
- APLS insider transactions and insider buying
- Is APLS undervalued or overvalued?
- Apellis Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- APLS Piotroski F-Score and Altman Z-Score
- APLS analyst price target and Smart Rating
Apellis Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
APLS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Apellis Pharmaceuticals Inc (APLS)
APLS trades 1729% above its Graham fair value of $1.22, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Apellis Pharmaceuticals Inc (APLS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Apellis Pharmaceuticals Inc (APLS) Key Strengths (2)
100.67% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Apellis Pharmaceuticals Inc (APLS) Areas to Watch (6)
Losing money on operations
Revenue declining -5.90%, a shrinking business
Very expensive at 5.9x book value
Very thin margins, barely profitable
Low profitability relative to shareholder equity
Revenue is fairly priced at 2.19x sales
Supporting Valuation Data
Apellis Pharmaceuticals Inc (APLS) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Book. Some valuation metrics including Price/Sales (2.19), Price/Book (5.94) suggest expensive pricing. Growth concerns include Revenue Growth at -5.90%, which may limit upside. Profitability pressure is visible in Return on Equity at 7.48%, Operating Margin at -25.60%, Profit Margin at 2.23%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 7.48% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -5.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
APLS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
APLS's Price-to-Sales ratio of 2.19x trades at a deep discount to its historical average of 43.08x (0th percentile). The current valuation is 99% below its historical high of 152.83x set in Jun 2023, and 0% above its historical low of 2.19x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Apellis Pharmaceuticals Inc (APLS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Apellis Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1.0B with 6% decline year-over-year. Profit margins are thin at 2.2%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue contracted 6% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -14M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Apellis Pharmaceuticals Inc push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 95.6x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Apellis Pharmaceuticals Inc.
Bottom Line
Apellis Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(56 last 3 months)
| Insider | Type | Shares |
|---|---|---|
DELONG, MARK JEFFREY Chief Business & Strat Officer | Sell | -368 |
| Insider | Type | Shares |
|---|---|---|
BAUMAL, CAROLINE Chief Medical Officer | Sell | -3,020 |
Data sourced from SEC Form 4 filings
Last updated: 10:00:58 AM
About Apellis Pharmaceuticals Inc(APLS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.